Byetta, Januvia/Janumet and Victoza

Subscribe to Byetta, Januvia/Janumet and Victoza

As we have previously reported, safety concerns regarding incretin mimetics (such as Byetta, Januvia/Janumet and Victoza), led to more than a thousand lawsuits being filed across the country. Reports suggest that people taking the medications for the treatment of Type 2 diabetes may be at an increased risk of developing pancreatic cancer.
…
Continue Reading Drugmakers React to Reinstatement of Incretin Mimetics Cases

Victoza (liraglutide), an injectable Type II diabetes drug, which works by stimulating insulin production by the pancreas, received approval from the U.S. Food and Drug Administration (“FDA”) in 2010.

When taken in high doses (3 milligrams), Victoza, manufactured by Novo Nordisk, has been shown to help individuals lose weight. The drug suppresses an individual’s appetite, as well as decreases the absorption of sugar from the digestive system, and slows movement of food through the digestive system.

In essence, the individual is likely to feel fuller for a longer period of time when taking Victoza. Accordingly, individuals began reporting weight loss while taking Victoza.

Subsequently, in August 2017, the FDA also approved Victoza to reduce the risk of heart attack, stroke, and cardiovascular death, in adults with Type II diabetes and established cardiovascular disease.…

Continue Reading Diabetes Drug, Victoza, May Have Weight Loss Benefits, but Allegedly Linked to an Increase Risk of Pancreatic Cancer

As we have previously reported, safety concerns regarding incretin mimetics (such as Byetta, Januvia/Janumet and Victoza), led to more than a thousand lawsuits being filed across the country.

Reports suggest that people taking the medications for the treatment of Type 2 diabetes may be at an increased risk of developing pancreatic cancer.

In August 2013, those lawsuits were consolidated in a Multi-District Litigation (MDL), before Judge Anthony J. Battaglia, in the United States District Court for the Southern District of California. The litigation suffered an unexpected setback when, in November 2015, the trial court granted summary judgment, essentially dismissing the claims.…

Continue Reading Incretin Mimetics Cases See Signs of New Life on Appeal

The U.S. Food and Drug Administration (FDA) warned that Type 2 diabetes drugs in the Dipeptidyl peptidase-4 (DPP-4) inhibitors class may cause severe joint pain. Januvia/Janumet (Sitagliptin) was developed and marketed by Merck & Co. as an oral anti-hyperglycemic beginning in 2006. It was the first approved medication in the DPP-4 class to hit the…

The litigation regarding incretin mimetics, such as Byetta, Januvia/Janumet and Victoza, continues to grow across the country. Byetta (Exenatide), manufactured by Amylin Pharmaceuticals, in association with Eli Lilly and Co., entered the market in 2005 for the treatment of Type 2 diabetes.  Byetta, now sold by Bristol-Myers Squibb and AstraZeneca, is a type of incretin…

As we have previously reported, the American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications (Januvia/Janumet/Byetta/Victoza) to make patient level data on their products available for an independent review. Research into the safety of these incretin medications continues across the globe.

A recent study published…

As we have previously reported, the United States Judicial Panel on Multidistrict Litigation (JPML) granted multidistrict litigation (MDL) treatment to the incretin mimetic litigation, meaning that all federal lawsuits filed across the United States are now centralized in one judicial district. The incretin mimetic litigation, which includes the medications Byetta, Januvia/Janumet and Victoza, was…

As we have previously reported, the United States Judicial Panel on Multidistrict Litigation (JPML) granted multidistrict litigation (MDL) treatment to the incretin mimetic litigation, meaning that all federal lawsuits filed across the United States are now centralized in one judicial district. The incretin mimetic litigation, which includes the medications Byetta, Januvia/Janumet and Victoza, was…

As we have previously reported, recent evidence suggests that incretin mimetic medications are linked to pancreatitis and pancreatic cancer. The American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications to make patient level data on their products available for an independent review. The ADA is…

As we previously reported, the United States Judicial Panel on Multi-District Litigation (MDL) convened to determine whether the cases, known as IN RE: INCRETIN MIMETICS PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the…